[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR091315A1 - Inhibidores de benzodioxano de la produccion de leucotrieno - Google Patents

Inhibidores de benzodioxano de la produccion de leucotrieno

Info

Publication number
AR091315A1
AR091315A1 ARP130100728A AR091315A1 AR 091315 A1 AR091315 A1 AR 091315A1 AR P130100728 A ARP130100728 A AR P130100728A AR 091315 A1 AR091315 A1 AR 091315A1
Authority
AR
Argentina
Prior art keywords
dihydro
dioxino
pyridin
benzyl
piperidin
Prior art date
Application number
Other languages
English (en)
Inventor
Martin Jr Kirrane Thomas
Russell Netherton Matthew
Razavi Hossein
Rodriguez Sonia
Saha Anjan
Sibley Robert
Louise Smith-Keenan Lana
Takahashi Hidenori
Robert Turner Michael
Wu Jiang
Richard Roush Ping-Young Erick
Zhang Qiang
Zhang Qing
M Zindell Renee
Richard Brunette Steven
j burke Michael
R Kapadia Suresh
Abeywardane Asitha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR091315A1 publication Critical patent/AR091315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Inhibidores de leucotrieno A₄ hidrolasa (LTA4H) y para el tratamiento de trastornos relacionados con LTA4H. También composiciones farmacéuticas que comprenden los compuestos de la fórmula (1), a los métodos de uso de estos compuestos en el tratamiento de varias enfermedades y trastornos, y a los procesos para preparar estos compuestos. Reivindicación 1: Un compuesto caracterizado porque es seleccionado del grupo que consiste de: ácido 3-[(4-{4-[(2S)-2,3-dihidro-1,4-benzodioxin-2-il]bencil}piperazin-1-il)metil]benzoico, etiléster del ácido 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazin-3-carboxílico, amida del ácido 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazin-3-carboxílico, metilamida del ácido 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirazin-3-carboxílico, amida del ácido 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-imidazo[1,2-a]pirazin-2-carboxílico, metilamida del ácido 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-imidazo[1,2-a]pirazin-2-carboxílico, amida del ácido 6-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-4H-1,2,3a,6-tetraaza-azulen-3-carboxílico, metilamida del ácido 6-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-4H-1,2,3a,6-tetraaza-azulen-3-carboxílico, ((S)-2-hidroxi-propil)-amida del ácido [(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3-aza-biciclo[3.1.0]hexan]-6-carboxílico, ((S)-2-hidroxi-1-metil-etil)-amida del ácido [(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3-aza-biciclo[3.1.0]hexan]-6-carboxílico, 7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-5,6,7,8-tetrahidro-imidazo[1,2-a]pirazin-3-carbonitrilo, N-{(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3-aza-biciclo[3.1.0]hex-6-il}-acetamida, (2-hidroxi-2-metil-propil)]-amida del ácido [(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3-aza-biciclo[3.1.0]hexan-6-carboxílico, N-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-il}-2-metoxi-acetamida, 1-{4-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperazin-1-il}-2-hidroxi-etanona, ácido 4-{1-[(S)-4-(2,3-dihidro-benzo[1,4]dioxin-2-il)-bencil]-azetidin-3-il}-benzoico, (2-hidroxi-2-metil-propil)-amida del ácido 1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-carboxílico, 1-{(1S,4S)-5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.1]hept-2-il}-2-metansulfonil-etanona, 1-{4-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-[1,4]diazepan-1-il}-2-metoxi-etanona, 5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-4,5,6,7-tetrahidro-tiazoIo[5,4-c]piridin-2-ilamina, {(endo)-8-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-8-aza-biciclo[3.2.1]oct-3-il}-urea, 2-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-il}-N-metoxi-acetamida, (R)-N-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-il}-2-metilamino-propionamida, N-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-ilmetil}-2-hidroxi-2-metil-propionamida, N-{(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3-aza-biciclo[3.1.0]hex-6-ilmetil}-metansulfonamida, 1-{(1S,4S)-5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.2]oct-2-il}-etanona, ácido 4-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-il}-ciclohexancarboxílico, ácido 1-[(S)-4-(2,3-dihidro-benzo[1,4]dioxin-2-il)-bencil}-azepan-4-carboxílico, ácido [(1a,5a,6a)-3-[(S)-4-(2,3-dihidro-benzo[1,4]dioxin-2-il)-bencil]-3-aza-biciclo[3.1.0]hexan]-6-carboxílico, amida del ácido (1S,4S)-5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.1]heptan-2-carboxílico, 1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-4-fenil-piperidin-4-oI, 1-{5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-hexahidro-pirrolo[3,4-c]pirrol-2-il}-etanona, 1-{8-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-3,8-diaza-biciclo[3.2.1]oct-3-il}-etanona, amida del ácido 5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-hexahidro-pirrolo[3,4-c]pirrol-2-carboxílico, {(exo)-8-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-8-aza-biciclo[3.2.1]oct-3-il}-urea, 2-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-iloxi}-acetamida, (S)-3-[4-(1,1-dioxo-1l⁶-[1,4]tiazepan-4-ilmetil)-fenil]-2,3-dihidro-[1,4]dioxino[2,3-b]piridina, 1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-4-metil-piperidin-4-oI, 1-{(1S,4S)-5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.1]hept-2-il}-2-hidroxi-etanona, N-{(endo)-8-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-8-aza-biciclo[3.2.1]oct-3-il}-acetamida, N-(1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-ilmetil}-acetamida, [(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-(1,1-dioxo-tetrahidro-1l⁶-tiofen-3-il)-metil-amina, 1-{(1S,4S)-5-[(S)-4-(2,3-dihidro-(1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.2]oct-2-il}-2-hidroxi-etanona, {1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-spiro-(3H-indol-3,4-piperidin]-1(2H)-urea, {1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-ilmetil}-urea, {4-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperazin-1-il}-acetonitrilo, (R)-7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-hexahidro-oxazolo[3,4-a]pirazin-3-ona, {1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-il}-(3-hidroxi-azetidin-1-il)-metanona, [(S)-1-(tetrahidro-furan-2-il)metil]-amida del ácido 1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-piperidin-4-carboxílico, N-[3-[4-[[4-[(3S)-2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il]fenil]metil]piperazin-1-il]-3-oxo-propil]acetamida, N-[1-[[4-[(3S)-2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il]fenil]metil]-4-piperidil]-2-(2-oxopirrolidin-1-il)acetamida, N-[1-[[4-[(3S)-2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il]fenil]metil]-4-piperidil]tetrahidropiran-4-carboxamida, 3-{1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il}-bencil]-piperidin-4-il}-[1,3]oxazinan-2-ona, 1-{(1S,4S)-5-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-2,5-diaza-biciclo[2.2.1]hept-2-il}-etanona, (S)-3-{4-[4-(piridin-3-iloxi)-piperidin-1-ilmetil]-fenil}-2,3-dihidro-[1,4]dioxino[2,3-b]piridina, ácido 1-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-4-fenil-piperidin-4-carboxílico, (S)-3-[4-(1-oxo-1l⁴-tiomorfolin-4-ilmetil)-fenil]-2,3-dihidro-[1,4]dioxino[2,3-b]piridina, y@@@(S)-7-[(S)-4-(2,3-dihidro-[1,4]dioxino[2,3-b]piridin-3-il)-bencil]-hexahidro-oxazolo[3,4-a]pirazin-3-ona, o una sal de aquel aceptable desde el punto de vista farmacéutico de cada uno de los anteriores.
ARP130100728 2012-03-06 2013-03-05 Inhibidores de benzodioxano de la produccion de leucotrieno AR091315A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607136P 2012-03-06 2012-03-06

Publications (1)

Publication Number Publication Date
AR091315A1 true AR091315A1 (es) 2015-01-28

Family

ID=47997798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100728 AR091315A1 (es) 2012-03-06 2013-03-05 Inhibidores de benzodioxano de la produccion de leucotrieno

Country Status (7)

Country Link
US (1) US8946203B2 (es)
EP (1) EP2822942B1 (es)
JP (1) JP6080227B2 (es)
AR (1) AR091315A1 (es)
TW (1) TW201350474A (es)
UY (1) UY34660A (es)
WO (1) WO2013134226A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036408T2 (hu) 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
JP5987220B2 (ja) 2011-07-19 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエンａ４ヒドロラーゼの阻害剤としてのアリールピラゾールエーテル
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
EP2885285B1 (en) 2012-07-17 2016-10-19 Boehringer Ingelheim International GmbH Pyrazole drivatives which inhibit leukotriene production
EP3022193B1 (en) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN105440041A (zh) * 2015-12-30 2016-03-30 上海药明康德新药开发有限公司 7-叔丁基-2-乙基-8-甲基-5,6-二氢咪唑[1,2-a]吡嗪-2,7（8H）-二羧酸的合成方法
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2023076679A1 (en) * 2021-11-01 2023-05-04 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918092A (en) 1983-12-21 1990-04-17 Merck Frosst Canada, Inc. Leukotriene antagonists
US5120758A (en) * 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
DE19821003A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EE200300195A (et) 2000-10-26 2003-10-15 Pfizer Products Inc. Pürimidiin-2,4,6-trioonmetalloproteinaasi inhibiitorid
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
PT1841757E (pt) 2005-01-07 2010-08-31 Pfizer Prod Inc Compostos de quinolina heteroaromáticos e respectiva utilização como inibidores de pde10
JP2008536825A (ja) 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルｌｔａ４ｈモジュレータ
US20070078263A1 (en) 2005-09-21 2007-04-05 Decode Chemistry, Inc. Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
EP1963276B9 (en) 2005-12-21 2012-09-26 Decode Genetics EHF N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
CA2721099C (en) * 2008-04-11 2017-04-25 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
CN102946877B (zh) 2010-03-18 2019-07-05 香港科技大学 乳突果及其分离的化合物在制备用于治疗神经疾病的药物中的用途
HUE036408T2 (hu) * 2011-03-14 2018-07-30 Boehringer Ingelheim Int A leukotrién-termelés benzodioxán inhibitorai
JP5987220B2 (ja) 2011-07-19 2016-09-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエンａ４ヒドロラーゼの阻害剤としてのアリールピラゾールエーテル
US8946203B2 (en) 2012-03-06 2015-02-03 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
US9662339B2 (en) * 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
EP2885285B1 (en) 2012-07-17 2016-10-19 Boehringer Ingelheim International GmbH Pyrazole drivatives which inhibit leukotriene production

Also Published As

Publication number Publication date
WO2013134226A1 (en) 2013-09-12
EP2822942B1 (en) 2017-05-10
UY34660A (es) 2013-09-30
JP2015512888A (ja) 2015-04-30
US8946203B2 (en) 2015-02-03
US20130244996A1 (en) 2013-09-19
TW201350474A (zh) 2013-12-16
EP2822942A1 (en) 2015-01-14
JP6080227B2 (ja) 2017-02-15

Similar Documents

Publication Publication Date Title
AR091315A1 (es) Inhibidores de benzodioxano de la produccion de leucotrieno
JP2015512888A5 (es)
JP2015513552A5 (es)
JP6080226B2 (ja) 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
JP2009509964A5 (es)
JP2015504057A5 (es)
JP2015523387A5 (es)
RU2015124917A (ru) Новые бициклические фенилпиридины/пиразины для лечения рака
JP2020522570A5 (es)
JP2011500774A5 (es)
JP2015508075A5 (es)
RU2015110500A (ru) Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
RU2016138788A (ru) Агонисты мускариновых рецепторов
PE20091353A1 (es) Nuevos compuestos heterociclicos
JP2009516743A5 (es)
JP2006503010A5 (es)
JP2017510564A5 (es)
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
JP2019530725A5 (es)
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
JP2016500694A5 (es)
JP2011506466A5 (es)
AU2019363662B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
NZ600593A (en) Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
AU2010273732A1 (en) 5-HT3 receptor modulators, methods of making, and use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure